The impact of multi-drug resistant Pseudomonas aeruginosa infections on acute pancreatitis patients.
Humans
Amikacin
/ therapeutic use
Pseudomonas aeruginosa
Pseudomonas Infections
/ drug therapy
Retrospective Studies
Case-Control Studies
Acute Disease
Drug Resistance, Multiple, Bacterial
Pancreatitis
/ complications
Anti-Bacterial Agents
/ pharmacology
Carbapenems
/ therapeutic use
Tobramycin
/ pharmacology
Gentamicins
/ therapeutic use
Microbial Sensitivity Tests
Acute pancreatitis
Drug resistance
Infection
Multi-drug resistant Pseudomonas aeruginosa
Risk factor
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
22 May 2023
22 May 2023
Historique:
received:
17
01
2023
accepted:
06
04
2023
medline:
24
5
2023
pubmed:
23
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
Acute pancreatitis (AP) accounts for a high proportion of digestive diseases worldwide and has a high risk of infection. Pseudomonas aeruginosa, a common pathogen of hospital infections, has been observed to increase the resistance rate to several antibiotics, causing difficulties in treatments. Our study aims to investigate the impact of the multi-drug resistant Pseudomonas aeruginosa (MDR-PA) infections on AP patients. At two Chinese tertiary referral centers for AP patients infected with MDR-PA, a retrospective case-control study with a 1:2 case-control ratio was performed. Comparisons were preformed between with/without MDR-PA infections and different drug-resistance of MDR-PA infections patients, respectively. Independent risk factors of overall mortality were assessed via univariate and multivariate binary logistic regression analyses, and the distribution and antibiotic resistant rates of strains were described. Mortality in AP patients with MDR-PA infections was significantly higher than in those without MDR-PA infections (7 (30.4%) vs. 4 (8.7%), P = 0.048). The rate of prophylactic use of carbapenem for 3 days (0 vs. 50%, P = 0.019) and the incidence rate of multiple organ failure (MOF) (0 vs. 57.1%, P = 0.018) were remarkably higher in the carbapenem-resistant Pseudomonas aeruginosa group compared with the carbapenem-sensitive Pseudomonas aeruginosa group. In the multivariate analysis, the severe categories of AP (OR = 13.624, 95% CIs = 1.567-118.491, P = 0.018) and MDR-PA infections (OR = 4.788, 95% CIs = 1.107-20.709, P = 0.036) were independent risk factors for mortality. The resistance rates of MDR-PA strains were low for amikacin (7.4%), tobramycin (3.7%), and gentamicin (18.5%). The resistance rates of MDR-PA strains to imipenem and meropenem were up to, 51.9% and 55.6%, respectively. In AP patients, severe categories of AP and MDR-PA infections were both independent risk factors for mortality. Inappropriate use of carbapenem antibiotics and MOF were related to carbapenem-resistant Pseudomonas aeruginosa infections. Amikacin, tobramycin, and gentamicin are recommended for the treatment of AP patients with MDR-PA infections.
Identifiants
pubmed: 37217844
doi: 10.1186/s12879-023-08230-y
pii: 10.1186/s12879-023-08230-y
pmc: PMC10201707
doi:
Substances chimiques
Amikacin
84319SGC3C
Anti-Bacterial Agents
0
Carbapenems
0
Tobramycin
VZ8RRZ51VK
Gentamicins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
340Subventions
Organisme : China Scholarship Council
ID : No. 202106370184
Organisme : China Scholarship Council
ID : No. 202106370184
Organisme : China Scholarship Council
ID : No. 202106370184
Organisme : China Scholarship Council
ID : No. 202106370184
Organisme : China Scholarship Council
ID : No. 202106370184
Organisme : China Scholarship Council
ID : No. 202106370184
Organisme : China Scholarship Council
ID : No. 202106370184
Organisme : National Natural Science Foundation of China
ID : Grant No. 81670589 and No. 82170661
Organisme : National Natural Science Foundation of China
ID : Grant No. 81670589 and No. 82170661
Organisme : National Natural Science Foundation of China
ID : Grant No. 81670589 and No. 82170661
Organisme : National Natural Science Foundation of China
ID : Grant No. 81670589 and No. 82170661
Organisme : National Natural Science Foundation of China
ID : Grant No. 81670589 and No. 82170661
Organisme : National Natural Science Foundation of China
ID : Grant No. 81670589 and No. 82170661
Organisme : National Natural Science Foundation of China
ID : Grant No. 81670589 and No. 82170661
Informations de copyright
© 2023. The Author(s).
Références
Gut. 2013 Jan;62(1):102-11
pubmed: 23100216
Drugs Context. 2018 May 29;7:212527
pubmed: 29872449
Gut. 2020 Mar;69(3):604-605
pubmed: 31233394
Microbiol Spectr. 2016 Apr;4(2):
pubmed: 27227291
Infect Dis Ther. 2022 Apr;11(2):661-682
pubmed: 35150435
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Braz J Anesthesiol. 2013 Jan-Feb;63(1):73-8
pubmed: 23438802
Gastroenterology. 2020 Jan;158(1):67-75.e1
pubmed: 31479658
Infect Dis Ther. 2021 Mar;10(1):559-573
pubmed: 33611687
Crit Care Med. 1995 Oct;23(10):1638-52
pubmed: 7587228
Pancreatology. 2019 Jun;19(4):488-499
pubmed: 31068256
Pancreatology. 2016 Sep-Oct;16(5):698-707
pubmed: 27449605
Shock. 2020 Mar;53(3):293-298
pubmed: 31390337
PLoS One. 2018 Feb 22;13(2):e0193431
pubmed: 29470531
J Pak Med Assoc. 2015 Jan;65(1):12-6
pubmed: 25831667
Antimicrob Agents Chemother. 2012 Dec;56(12):6434-6
pubmed: 23070164
Gastroenterology. 2022 Jan;162(1):122-134
pubmed: 34571026
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301
pubmed: 27573805
Infect Dis Ther. 2021 Sep;10(3):1665-1676
pubmed: 34215975
BMC Infect Dis. 2021 Sep 20;21(1):977
pubmed: 34544384
Infect Dis Ther. 2022 Jun;11(3):1089-1101
pubmed: 35377132
Biotechnol Adv. 2019 Jan - Feb;37(1):177-192
pubmed: 30500353
J Intensive Care Med. 2018 May;33(5):296-309
pubmed: 27756870
Clin Transl Gastroenterol. 2018 Oct 5;9(10):190
pubmed: 30287818
Drugs. 2022 Aug;82(12):1251-1276
pubmed: 36074322
Int J Mol Sci. 2021 Nov 29;22(23):
pubmed: 34884697
Indian J Anaesth. 2014 Jan;58(1):30-5
pubmed: 24700896
Front Cell Infect Microbiol. 2022 Nov 24;12:1044188
pubmed: 36506015
Infection. 2021 Aug;49(4):769-774
pubmed: 33988828
PLoS One. 2021 Nov 15;16(11):e0257272
pubmed: 34780494
Pancreatology. 2019 Oct;19(7):935-940
pubmed: 31558390
Infect Drug Resist. 2018 Nov 16;11:2345-2356
pubmed: 30532566
Lancet. 2020 Sep 5;396(10252):726-734
pubmed: 32891214
Inflamm Res. 2012 Jul;61(7):743-8
pubmed: 22466614
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):175-184
pubmed: 30482911
BMC Health Serv Res. 2012 May 23;12:122
pubmed: 22621745
PLoS One. 2013 Nov 08;8(11):e78604
pubmed: 24250801
Rev Soc Bras Med Trop. 2019 Dec 20;53:e20180498
pubmed: 31859938
Infect Control Hosp Epidemiol. 2020 Jan;41(1):1-18
pubmed: 31767041
Nephron. 2015;131(3):153-60
pubmed: 26389593
Pancreatology. 2022 Mar;22(2):194-199
pubmed: 34924296
Clin Microbiol Rev. 2019 Oct 30;33(1):
pubmed: 31666280
Pancreatology. 2018 Dec;18(8):870-877
pubmed: 30337224